of Engineering and Natural Sciences
Akt and mitochondrial priming: targeting
PTEN-null cancer cells
Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston,
in PI3K/Akt pathway are frequently found in
human cancer. PTEN is a lipid
phosphatase that selectively dephosphorylates phosphoinositides and
effects of PI3K. Loss or inactivating mutations of PTEN results in
activation of PI3K/Akt pathway. Considering its prosurvival effect,
PI3K/Akt pathway can sensitize cancer cells to programmed cell death. In our studies, we investigated the
regulation of mitochondrial priming by Akt signaling in PTEN-null
cells. Our results underscore the direct
role of Akt in the regulation of mitochondrial cell death and
Bcl-2 inhibition in PTEN-null cancer cells.
Kütük got his MD degree from Marmara University School of Medicine
in 2000 and his PhD degree from Sabanci University Biological Sciences
Bioengineering Program in 2006.
his PhD education, he was granted fellowships from FEBS and EACR
to wotk as a visiting scientist at Karolinska Center
for Cancer. He
started his postdoctoral fellowship in Dana-Farber Cancer Institute at Harvard Medical School
in 2006 and currently works as Terri Brodeur Breast Cancer Foundation
Dr. Anthony Letai’s lab at DFCI/HMS.
2010, 12:40, FENS G032